guest ::
| Home > Publications database > Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation. > print |
| Home > Publications database > Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation. > print |
| 001 | 128915 | ||
| 005 | 20240228143357.0 | ||
| 024 | 7 | _ | |a 10.1155/2016/6078473 |2 doi |
| 024 | 7 | _ | |a pmid:27446966 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4942663 |2 pmc |
| 024 | 7 | _ | |a 2314-7156 |2 ISSN |
| 024 | 7 | _ | |a 2314-8861 |2 ISSN |
| 024 | 7 | _ | |a altmetric:10020855 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-04928 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Knippertz, Ilka |0 0000-0002-2866-3901 |b 0 |
| 245 | _ | _ | |a Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation. |
| 260 | _ | _ | |a New York, NY |c 2016 |b Hindawi |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1526285532_12663 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a To specifically target dendritic cells (DCs) to simultaneously express different therapeutic transgenes for inducing immune responses against tumors, we used a combined promoter system of adenoviral vectors. We selected a 216 bp short Hsp70B' core promoter induced by a mutated, constitutively active heat shock factor (mHSF) 1 to drive strong gene expression of therapeutic transgenes MelanA, BclxL, and IL-12p70 in HeLa cells, as well as in mature DCs (mDCs). As this involves overexpressing mHSF1, we first evaluated the resulting effects on DCs regarding upregulation of heat shock proteins and maturation markers, toxicity, cytokine profile, and capacity to induce antigen-specific CD8(+) T cells. Second, we generated the two-vector-based 'modular promoter' system, where one vector contains the mHSF1 under the control of the human CD83 promoter, which is specifically active only in DCs and after maturation. mHSF1, in turn, activates the Hsp70B' core promotor-driven expression of transgenes MelanA and IL-12p70 in the DC-like cell line XS52 and in human mature and hence immunogenic DCs, but not in tolerogenic immature DCs. These in vitro experiments provide the basis for an in vivo targeting of mature DCs for the expression of multiple transgenes. Therefore, this modular promoter system represents a promising tool for future DC-based immunotherapies in vivo. |
| 536 | _ | _ | |a 316 - Infections and cancer (POF3-316) |0 G:(DE-HGF)POF3-316 |c POF3-316 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Antigens, CD |2 NLM Chemicals |
| 650 | _ | 7 | |a BCL2L1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a CD83 antigen |2 NLM Chemicals |
| 650 | _ | 7 | |a Cytokines |2 NLM Chemicals |
| 650 | _ | 7 | |a DNA-Binding Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Immunoglobulins |2 NLM Chemicals |
| 650 | _ | 7 | |a MART-1 Antigen |2 NLM Chemicals |
| 650 | _ | 7 | |a Membrane Glycoproteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Transcription Factors |2 NLM Chemicals |
| 650 | _ | 7 | |a bcl-X Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a heat shock transcription factor |2 NLM Chemicals |
| 650 | _ | 7 | |a Interleukin-12 |0 187348-17-0 |2 NLM Chemicals |
| 700 | 1 | _ | |a Deinzer, Andrea |b 1 |
| 700 | 1 | _ | |a Dörrie, Jan |0 0000-0002-3478-0741 |b 2 |
| 700 | 1 | _ | |a Schaft, Niels |0 0000-0001-8236-9298 |b 3 |
| 700 | 1 | _ | |a Nettelbeck, Dirk M |0 0000-0002-1225-2593 |b 4 |
| 700 | 1 | _ | |a Steinkasserer, Alexander |0 0000-0001-7187-6729 |b 5 |
| 773 | _ | _ | |a 10.1155/2016/6078473 |g Vol. 2016, p. 1 - 17 |0 PERI:(DE-600)2817541-4 |p 1 - 17 |t Journal of Immunology Research |v 2016 |y 2016 |x 2314-7156 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:128915 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 0000-0002-1225-2593 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-316 |2 G:(DE-HGF)POF3-300 |v Infections and cancer |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J IMMUNOL RES : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)F110-20160331 |k F110 |l Onkolytische Adenoviren |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F110-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|